Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 19Docetaxel 17Cetuximab 12Carboplatin 12Radiotherapy 11Magnetic Resonance Spectroscopy 10Biopsy 10pembrolizumab 9Paclitaxel 9Radiotherapy, Intensity-Modulated 8Immunohistochemistry 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Chemotherapy, Adjuvant 7Specimen Handling 6Radiotherapy, Conformal 5Radiosurgery 5Gene Expression Profiling 5Fluorodeoxyglucose F18 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Polymerase Chain Reaction 4Nivolumab 4Bevacizumab 4trastuzumab deruxtecan 3sargramostim 3bicalutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × MK 2206 × Head & Neck × Clear all
NCT01604772 2019-05-01

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 7 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡